Anticipate Bioscience is built on 5 years of world class medicinal chemistry by a veteran oncology research team at www.td2inc.com. We have two development candidate small molecules, that are both 12 months from IND. The first is a ROCK1 inhibitor where we are targeting a novel NGS addressable mutation that covers 5-8% of solid tumors across a wide range of mutations (80,000 annual patients). It is on existing NGS panels and the precinical data packages shows strong shutdown effect of tumors with this mutation to our sub-nano molar ROCK1 inhibitors. The second program targets myelofibrosis and shuts down two pathways critical to disease progression. The SAB includes world-class oncologists, including three former cancer society presidents. The team has strong experience in cancer drug development, and this is the CEO's third oncology company, with prior successes and strong investor exits at Ignyta, Quest Diagnostics, Aperio, and Flagship Biosciences.
Speaker
